Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616148 · ClinicalTrials.gov registry record · Phase 2
Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
A Phase 2 study of Epilepsy, sponsored by SK Life Science.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
- 4
- Study locations
NCT00616148: Completed Phase 2 study of Epilepsy, sponsored by SK Life Science.
NCT00616148 is a Phase 2 study of Epilepsy that has completed, run by SK Life Science. The registered enrollment target is 11 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00616148, a Phase 2 study of Epilepsy, has completed, sponsored by SK Life Science.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
- 4
- Study locations
Study Summary
The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investigate different doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG YKP3089
Study Locations (4)
New York
- Cornell Medical Center - New York
- Montefiore Medical Center - The Bronx
Maryland
- Johns Hopkins Medical Center - Baltimore
Pennsylvania
- University of Pennsylvania Epilepsy Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00616148 record still lists
NCT00616148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00616148 reports a single indexed study location in New York, Maryland, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00616148 about?
NCT00616148 is a clinical study titled "Efficacy of YKP3089 in Patients With Photosensitive Epilepsy". The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy patients, and to measure the onset and duration of the effect. Several cohorts will be used, to sequentially investi...
What is the current status of trial NCT00616148?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2007-08. Estimated completion is 2010-01.
What conditions does trial NCT00616148 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00616148?
The interventions under investigation include: Placebo (DRUG), YKP3089 (DRUG).
Who is sponsoring clinical trial NCT00616148?
This trial is sponsored by SK Life Science, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616148 being conducted?
This trial has 4 study locations across Maryland, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00616148's enrollment target sits among peer trials
11 146th of 160 higher than 14 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
RECRUITING · Phase 2
-
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Study of an External Responsive Neurostimulator System on Epileptiform Activity
COMPLETED · Phase 2
-
Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI
COMPLETED · Phase 2
-
Hormone Replacement in Menopausal Women With Epilepsy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia